2-((1S,2S,5S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)acetic acid → 2-[(1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-N-[4-(4-methylphenyl)-1-oxophthalazin-2(1H)-yl]acetamide

Participants

Reaction Steps

The product of Example 135A and 2-[(1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]acetic acid were treated using a method similar to that described in Example 17C to give the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 11.34 (s, 1H), 8.37-8.41 (m, 1H), 7.86-8.04 (m, 2H), 7.72-7.77 (m, 1H), 7.46-7.50 (m, 2H), 7.36-7.40 (m, 2H), 2.51-2.60 (m, 2H), 2.42 (s, 3H), 2.29-2.45 (m, 2H), 1.79-2.06 (m, 5H), 1.47-1.63 (m, 1H), 1.20 (s, 3H), 1.07 (d, J=0.6 Hz, 3H), 0.91 (d, J=9.5 Hz, 1H); MS (APCI+) M/Z 416 (M+H)+.

Provenance & Evidence